Tumour overexpression of uPA/uPAR and the related uPA inhibitor PAI-1 (SERPINE1) strongly correlates to metastatic potential [12-16] and poor patient prognosis [17-20], but the presence of PAI-2 is associated with benign tumours and increased, relapse-free survival [9]. Here, SERPINE1 is linked to benign neoplasm.